Kornimate/medical-research-clean huggingface dataset:
hormonal outcomes in acromegalic patients with treated surgery with or without long acting somatostatin analogues

Conditions: Acromegaly

Summary: long-term (up to 3 years) clinical and hormonal outcomes in acromegalic patients with treated surgery with or without long acting somatostatin analogues.

patients who are diagnosed with acromegaly with a gh-secreting pituitary adenoma receiving tsa at the asan medical center (seoul, korea) from aug 2013 to aug 2015 will be recruited. the eligible patient population will consist of 30 adult, male and female patient with age 18 or older. * number of patients by treatment group: surgical treatment only = 15, surgery with medical treatment = 15 * number of centers: 1 (single center)

Eligibility criteria:
inclusion criteria: 1. age 18 or older. 2. patients diagnosed with acromegaly with gh-secreting pituitary adenoma on sellar mri, meeting the biochemical criteria outlined above (refer to 1. diagnosis of acromegaly) and with typical acromegalic features. 3. no prior use of somatostatin analogues. 4. adequate hepatic and renal function 5. provision of a signed written informed consent exclusion criteria: 1. severe co-morbid illness such as untreatable other malignancy and/or active infections. 2. pregnant or lactating women 3. hypersensitivity to sandostatin or any component of the formulation.
agrylin drug use-result survey

Conditions: Essential Thrombocythemia (ET)

Summary: the objective of this survey is to collect data to evaluate the safety and efficacy of anagrelide hydrochloride in the post-marketing phase in participants diagnosed with essential thrombocythemia (et).

anagrelide hydrochloride drug use-result survey

Eligibility criteria:
inclusion criteria: - all cases who received treatment with agrylin. exclusion criteria: -
multiple sclerosis: the role of mitochondrial dysfunction in ir resistance

Conditions: Multiple Sclerosis; Mitochondrial Alteration

Summary: multiple sclerosis (ms) is a chronic inflammatory demyelinating disease of the central nervous system (cns) and is one of the most common neurological diseases, often leading to disability of the patients. the ms pathogenesis includes vascular and inflammatory components, however recently also the role of mitochondrial dysfunction being a hot topic in neurodegeneration.

multiple sclerosis (ms) is a chronic inflammatory demyelinating disease of the central nervous system (cns) and is one of the most common neurological diseases, often leading to disability of the patients. the ms pathogenesis includes vascular and inflammatory components, however recently also the role of mitochondrial dysfunction being a hot topic in neurodegeneration. current project is based on previous project results, where the investigators of this project found signs of insulin resistance (ir) with hyperinsulinemia in patients with ms, which seem not to be related to chronic inflammation or low physical activity. therefore aim of the present project is to elucidate impact of mitochondrial dysfunction in the pathogenesis of impaired insulin action and its role in the neurodegenerative process. to test the hypothesis, mitochondrial function, endothelial function, changes in membrane proteins and function of autonomic nervous system will be assessed. those parameters will be measured non-invasively and in samples of blood, cerebrospinal fluid and skeletal muscle. ms patients will be examined at the time of diagnosis and after 12 months of treatment; healthy subjects will be used as controls. elucidation of insulin resistance cause and the role of mitochondrial dysfunction in pathogenesis of disease is expected. potential outcome of the project could be the answer, if pharmacological or non-pharmacological intervention might lead to improvement of mitochondrial function and therefore represent a new approach to prevent ms progression.

Eligibility criteria:
inclusion criteria for ms patients: * age: 18-45 years * recent diagnosis of ms based on mcdonald criteria * functional disability defined by the edds in the range of 2 to 6 * patient demonstrates ability to successfully perform physical therapy exercises and procedures independently or with assistance of a caregiver exclusion criteria: * smoking, pregnancy, lactation, received a course of steroids (intravenous or oral) within 60 days of screening, diabetes, hypertension
efficacy of faviprevir in covid-19 treatment

Conditions: COVID

Summary: faviprevir in covid-19 treatment

clinical study evaluating the efficacy of faviprevir in covid-19 treatment

Eligibility criteria:
inclusion criteria: * patients with covid 19 exclusion criteria: * allergy or contraindications to faviprevir
uark 2009-99 a non-interventional observational study of infectious complications in cancer patients

Conditions: Aspergillosis; Candidemia; C. Difficile

Summary: observational study of infectious complications in cancer patients

a non-interventional, observational study of infectious complications in cancer patients

Eligibility criteria:
inclusion criteria: * cancer patients with infections exclusion criteria: * no infections

Keywords: aspergillosis candidemia candidiasis c. difficile cytomegalovirus respiratory syncytial virus (rsv) influenza cons
albi and palbi scores and hcc prognosis

Conditions: Hepatocellular Carcinoma (HCC) Prognosis

Summary: to compare the predictive ability of albi and palbi grades with ctp and meld scores. to investigate the efficacy of albi and palbi grades for predicting the prognosis of hcc and overall survival among different modalities of treatment.


Eligibility criteria:
inclusion criteria: • the diagnosis of hcc will be based on the presence of an arterial hypervascular focal lesion \> 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (ct), or dynamic magnetic resonance imaging (mri)) or two imaging modalities demonstrating the before mentioned feature for lesions \< 2 cm with or without elevated serum alpha-fetoprotein (afp) levels. exclusion criteria: * patients below 18 years old. * patients with pre-existing other malignancies. * patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases. * patients with pre-existing haematologic disorders. * patients with proteinuria. * missed follow-up.
a study of intravitreal iluvien® implant as baseline therapy in patients with early diabetic macular edema (dme)

Conditions: Diabetic Macular Edema

Summary: this is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of iluvien as a baseline therapy in the treatment of center involving dme (ci-dme). the study will enroll patients who are either treatment naïve or have not received any dme treatments for the preceding 12 months as documented in medical records. patients who received dme treatment \>12 months before screening, must not have received \>4 intravitreal injections. the study will compare 2 treatment regimens: iluvien intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 ml), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 ml).


Eligibility criteria:
major inclusion criteria: 1. male or female subjects ≥18 years of age at the time of consent. 2. must have ci-dme confirmed by spectral domain ocular coherence tomography (sd-oct) and center subfield thickness (cst) of: ≥350 µm in the study eye. 3. best corrected visual acuity (bcva) of ≤80 etdrs letters and ≥35 etdrs letters in the study eye at screening visit. major exclusion criteria: 1. patients with proliferative diabetic retinopathy (pdr); high risk proliferative diabetic retinopathy in the study eye and related complications. 2. history or current diagnosis of glaucoma or ocular hypertension (oht) or a cup to disc ratio \>0.8; history of uncontrolled intraocular pressure (defined as iop ≥25 mmhg with maximum topical and systemic medical hypotensive treatment) or previous filtration surgery in the study eye at screening visit. 3. other conditions that can cause macular edema. 4. patients who received prior laser photocoagulation therapy including macular grid or pan retina photocoagulation (prp) at any time in the study eye. prior focal laser photocoagulation therapy outside the macula is allowed. 5. patients who received the following therapies in the study eye: 1. intravitreal or periocular steroids; 2. intravitreal injection of aflibercept, brolucizumab, or conbercept ≤12 months prior to screening visit 6. patients who received \>1 intravitreal injection of ranibizumab or bevacizumab in the last 12 months; or have received ranibizumab or bevacizumab ≤6 weeks prior to screening visit 7. patients who have lens opacities due to cataract or other etiologies that would make it difficult to examine the fundus or that affect the patients activities of daily living (adl). 8. steroid challenge exclusion criterion- at the baseline visit, patients who are determined to have an iop ≥25 mmhg or an increase ≥8 mmhg from screening will be excluded from the study.

Keywords: dme ci-dme diabetic macular edema diabetic retinopathy
improving therapeutic adherence with a co-constructed program involving both patients and health care professionals

Conditions: Cystic Fibrosis

Summary: background cystic fibrosis is a life-threatening genetic disorder responsible for pulmonary failure and multi-systemic complications involving specific and large medical care burden. to date, no program has shown its effectiveness in improving therapeutic adherence. a new approach to develop a co-constructed program involving patients and professionals may contribute to improve therapeutic adherence. objectives the aim of the mucobs-trial project is to create a program to increase therapeutic adherence and to evaluate its efficacy in adult patients with cystic fibrosis in 3 cf centers in france.


Eligibility criteria:
inclusion criteria: * patients with cystic fibrosis * aged 18 or more * speaking / understanding french * followed in one of the participating centers (crcm of the auvergne-rhône-alpes region) * resident in auvergne-rhône-alpes * affiliated to the general health insurance scheme exclusion criteria: * transplanted patients * patients who participated in the working group for the co-construction of the intervention

Keywords: cystic fibrosis therapeutic adherence co-constructed intervention patient involvement
the effect of transcranial direct current stimulation on visual attention - single sessions

Conditions: Healthy Aging; Cognitive Change; Cognitive Decline

Summary: recently, attention has been drawn to non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tdcs), in order to enhance cognitive functions by modifying brain plasticity and use it in different healthy and diseased populations. in the current research, investigator aim to examine the short-term effects of multiple tdcs protocols in healthy adults population on visual attention and identify the neural underpinnings of tdcs-induced behavioral aftereffects using a combined tdcs/ mri network-based approach.

investigator will investigate the shor-term effects of active tdcs as compared to a placebo stimulation on visual attention in the healthy seniors. a cross-over, randomized, placebo-controlled design will be used. single tdcs sessions will be performed in 4 sessions over distinct brain areas with ongoing visual attention training. during the stimulation, investigator will use the visual matching task. mri protocol consisting of t1 and resting state fmri sequences will be acquired before and after every stimulation session in order to search for active vs. placebo tdcs-induced changes in brain activation and resting state functional connectivity and to identify neural correlates of behavioral changes.

Eligibility criteria:
inclusion criteria: * right handed, healthy volunteers in two groups - healthy adults under 40 years, healthy seniors over 50 years exclusion criteria: * psychiatric disorders, including major depression, major vascular lesions, and other brain pathologies detected by mri that might present with cognitive decline * a cardio pacemaker or any mri-incompatible metal in the body * epilepsy * any diagnosed psychiatric disorder * alcohol/drug abuse * lack of cooperation * presence of cognitive impairment

Keywords: transcranial direct current stimulation healthy seniors healthy adults
decreasing the use of unmodified electroconvulsive therapy (ect) in an indian hospital

Conditions: Major Depressive Disorder; Bipolar Disorder; Schizophrenia

Summary: in developing countries, electroconvulsive therapy (ect) is typically delivered without the use of an anesthetic prior to the treatment, known as unmodified ect. this interventional study aims to decrease the practice of unmodified ect at chhatrapati shahuji maharaj medical university, u.p. \& g.m. \& associated hospitals (c.s.m) by administering a low dose anesthetic (propofol) prior to ect delivery. in so doing, the investigators hope to facilitate the transition from unmodified to modified ect without incurring excessive costs to the center. it is hypothesized that ect patients will opt for modified treatment, that adverse effects will be minimal, and that costs will not rise prohibitively.

patients that are currently receiving unmodified ect at c.s.m hospital will be eligible for the first phase of the study in which only data is collected. three months after study start, patients who are to receive ect for a psychiatric disorder will be eligible to participate in the intervention (introduction of propofol at a low dose prior to ect). data collection will include information such as demographics, ratings scales, seizure length, anxiety level, adverse events, and number of treatments.

Eligibility criteria:
inclusion criteria: * subjects are any psychiatric patients at c.s.m. for whom ect is recommended by their doctor, whether or not they actually receive ect. * subjects must also have an american society for anesthesiologists (asa) rating score of 1 (completely healthy) or 2 (mild systemic disease) with stable symptoms and laboratory values. * subjects must be between the ages of 18 to 65 years old and be able to give informed consent. exclusion criteria: * patients who speak neither english nor hindi. * history of or anatomical evidence for a difficult airway being a short mandible, micrognathia, large tongue or large goiter, arthritis of the jaw or neck, or enlarged tonsils. for this reason we will also exclude patients with a bmi \> 28. * respiratory tract disease including asthma, respiratory infection, chest wall disease, chronic obstructive pulmonary disease, obstructive sleep apnea, or other disorder which might compromise the airway. patients who smoke 15 or more cigarettes per day will be excluded unless abstinent for at least 10 days, to reduce the risk of respiratory complications. * patients who receive modified ect during the first phase of the study. * pregnant women or women who are breastfeeding. * hypersensitivity to propofol or any of its components. * patients who are hemodynamically unstable or who have impaired cardiac function. * bmi \< 18. * patients with a history of epilepsy

Keywords: electroconvulsive therapy ect unmodified anesthesia propofol
bone microarchitecture in osteopenic postmenopausal women

Conditions: Osteoporosis

Summary: the purpose of this trial is to compare the difference in bone microarchitecture of the distal radius at month 12 in postmenopausal osteopenic women treated with risedronate 150mg taken once a month compared to placebo.


Eligibility criteria:
inclusion criteria: * female: 40 and 57 years of age inclusive * cessation of menstruation (surgical or natural) between 12 and 36 months prior to study enrollment * have osteopenia defines as having the following: have osteopenia defined as having the following: * lumbar spine (l1-l4) bone mineral density (bmd) t score -1 and less than -2.5 and a total hip t score of greater than -2.5 or * lumbar spine (l1-l4) bmd t score greater than -2.5 and a total hip t score -1 and less than -2.5; * have a body mass index (bmi) between 18 and 30 kg/m2. exclusion criteria: * history of uncontrolled hyperparathyroidism, hyperthyroidism, osteomalacia * use of medications within 3 months of starting study drug that impact bone metabolism such as glucocorticoids, estrogens, calcitonin, calcitriol, other bisphosphonates and parathyroid hormone * hypocalcemia or hypercalcemia of any cause
registry of pancreatic fluid collections and pancreatic cysts

Conditions: Pancreatic Fluid Collections; Pancreatic Cyst

Summary: this registry aims to assess the outcomes of patients undergoing eus-guided interventions of pancreatic fluid collections and eus examination of pancreatic cyst lesions.

for pancreatic fluid collections, data included in this registry are 292 variables on patient demographics (age, gender, race), symptoms at presentation, severity of disease prior to intervention, indications for undergoing endoscopic intervention, details of the pancreatic fluid collections on cross-sectional imaging and eus, review of laboratory results, review of imaging, details of interventions performed for pancreatic fluid collections, clinical details following intervention, adverse events from interventions and pancreatitis/pancreatic fluid collections, interventions for any adverse events, response to treatment of pancreatic fluid collections including any hospital readmissions, recurrence of pancreatic fluid collections, need for repeat interventions for pancreatic fluid collections, details of pancreatic duct integrity such as the presence of disconnected pancreatic duct syndrome, and clinical status at follow-up. for pancreatic cysts, data included in this registry are 60 variables on patient demographics (age, gender, race), symptoms at presentation, imaging modality performed to detect the cyst, features of the cyst on eus, features of the main pancreatic duct on eus, technical details of eus-guided sampling of the cystic fluid, results of cyst fluid analysis including cytology, tumor markers, amylase levels, molecular markers, final diagnosis of the cyst on follow-up, details of any follow up evaluation performed, details of repeat examinations performed and details of any treatment performed for the pancreatic cyst.

Eligibility criteria:
inclusion criteria: 1. all patients aged 18 years or over, who are undergoing eus evaluation of a pancreatic cyst lesion or endoscopy-based (eus-guided) interventions for pancreatic fluid collection at the center for interventional endoscopy will be included in this registry. exclusion criteria 1. age less than 18 years 2. no pancreatic cyst on eus examination or no pancreatic fluid collection amenable to endoscopic drainage on eus examination
electrostimulation and pfmt for stress urinary incontinence

Conditions: Urinary Incontinence, Stress

Summary: the goal of this randomized controlled trial is to evaluate and compare the effects of electrostimulation in addition to pelvic floor muscle training and pelvic floor muscle training alone on pelvic floor muscle (pfm) function, urinary incontinence and quality of life in women with stress urinary incontinence. the main questions are: what is the effect of electrostimulation combined with pelvic floor muscle training on pelvic floor muscle function, symptoms of urinary incontinence and quality of life in women with stress urinary incontinence? what is the effect of pelvic floor muscle training program on pelvic floor muscle function, symptoms of urinary incontinence and quality of life in women with stress urinary incontinence? which intervention is more effective - electrostimulation with pelvic floor muscle training or pelvic floor muscle training alone? participants will be evaluated before and after the interventions with the following methods: international incontinence counseling questionnaire - short form (iciq-sf) pelvic floor muscle strength and endurance will be assessed with a "pelvexiser" perineometer.

the study involved 24 women 20-49 years old who have complained of stress urinary incontinence for at least 4 weeks, who gave at least one birth vaginally and signed the consent form. subjects were excluded if they were pregnant, were diagnosed with vaginismus, urinary tract infections, cancer, epilepsy, pelvic organ prolapse greater than stage i, skin diseases, had undergone previous pelvic floor surgeries, had heart stimulator, or metal implant and were unable to contract the pfm. study participants were randomly divided into two groups: the i group (n=12), in which participants underwent pelvic floor muscle training (pfmt) and the ii group (n=12) in which subjects received pelvic floor muscle exercises combined with electrostimulation (pfmes).participants were evaluated before the interventions and repeated after 4 weeks. before and after the interventions, women's quality of life (qol) was assessed according to the international incontinence counseling questionnaire - short form. perineometry with pelvexiser perineometer was used to measure pelvic floor muscle strength and endurance and vaginal resting pressure. statistical analysis was performed by ibm spss statistics 26.0 and microsoft excel software 365.

Eligibility criteria:
inclusion criteria: * have given birth at least once * voluntary consent to participate in the study * do not have concomitant diseases * do not use hormonal drugs. exclusion criteria: * less than three months have passed after childbirth * have heart implants or other metal implants * pregnancy

Keywords: stress incontinence pelvic floor electrostimulation muscle training